How has Jonathan Mow's remuneration changed compared to PhaseBio Pharmaceuticals's earnings?
Date
Total Compensation
Salary
Company Earnings
Jun 30 2022
n/a
n/a
-US$103m
Mar 31 2022
n/a
n/a
-US$115m
Dec 31 2021
US$2m
US$562k
-US$131m
Sep 30 2021
n/a
n/a
-US$118m
Jun 30 2021
n/a
n/a
-US$112m
Mar 31 2021
n/a
n/a
-US$111m
Dec 31 2020
US$2m
US$529k
-US$99m
Sep 30 2020
n/a
n/a
-US$80m
Jun 30 2020
n/a
n/a
-US$66m
Mar 31 2020
n/a
n/a
-US$47m
Dec 31 2019
US$1m
US$436k
-US$39m
Sep 30 2019
n/a
n/a
-US$33m
Jun 30 2019
n/a
n/a
-US$29m
Mar 31 2019
n/a
n/a
-US$27m
Dec 31 2018
US$596k
US$359k
-US$24m
Sep 30 2018
n/a
n/a
-US$22m
Jun 30 2018
n/a
n/a
-US$16m
Mar 31 2018
n/a
n/a
-US$12m
Dec 31 2017
US$436k
US$338k
-US$10m
Compensation vs Market: Insufficient data to establish whether Jonathan's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Jonathan's compensation with company performance.
CEO
Jonathan Mow (59 yo)
9.5yrs
Tenure
US$1,529,108
Compensation
Mr. Jonathan P. Mow, MBA, serves as Chief Executive Officer of Veralox Therapeutics Inc. since June 2023 and serves as its Director. He has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. si...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Jonathan Mow
President
9.5yrs
US$1.53m
no data
Lawrence Perkins
Chief Restructuring Officer & Principal Financial Officer
1.8yrs
no data
no data
Susan Arnold
Senior Vice President of Technical Operations
2.9yrs
no data
no data
Kristopher Hanson
SVP, General Counsel & Corporate Secretary
4.9yrs
no data
no data
Glen Burkhardt
Senior Vice President of Human Resources
4.9yrs
no data
no data
Jonathan Birchall
Chief Commercial Officer
2.8yrs
no data
no data
3.9yrs
Average Tenure
53.5yo
Average Age
Experienced Management: PHAS.Q's management team is considered experienced (3.9 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Jonathan Mow
President
10yrs
US$1.53m
no data
Richard van den Broek
Independent Director
5.6yrs
US$82.86k
no data
Edmund Harrigan
Independent Director
5.8yrs
US$76.36k
0.020% $ 0.01
Clay Thorp
Independent Chairman of the Board
22.7yrs
US$116.36k
0.074% $ 0.04
William Humphries
Independent Director
3yrs
US$62.58k
0.0051% $ 0.002
Nancy Hutson
Independent Director
6.5yrs
US$87.36k
0.083% $ 0.04
Alexander Sapir
Independent Director
4.6yrs
US$77.86k
0.0075% $ 0.004
5.8yrs
Average Tenure
58yo
Average Age
Experienced Board: PHAS.Q's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/09/12 08:58
End of Day Share Price
2024/09/12 00:00
Earnings
2022/06/30
Annual Earnings
2021/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PhaseBio Pharmaceuticals, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.